t(7;7)(q34;q36) AGAP3::BRAF
Oncogenic mechanisms
Activation of MAPK pathway
Targeted therapy
Cobimetinib
trametinib
Tumor type
Melanoma
colorectal carcinoma
non-small cell lung carcinoma
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 39687148 | 2024 | Rare BRAF gene fusions in metastatic early-onset colon cancer: A case report. | 31 |
| 35949061 | 2022 | AGAP3: A novel BRAF fusion partner in pediatric pancreatic-type acinar cell carcinoma. | 25 |
| 35871080 | 2022 | Identification of fusions with potential clinical significance in melanoma. | 0 |
| 28539463 | 2017 | BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAF(V600E) Mutant Melanoma. | 0 |
Bibliography
| Pubmed ID | Publication Year | Title | Authors |
|---|---|---|---|
| 28539463 | 2017 | BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. | Kulkarni A, et al |
| 26314551 | 2016 | The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. | Ross JS, et al |
| 29883838 | 2018 | Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. | Schrock AB, et al |
| 28512242 | 2017 | A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. | Kloosterman WP, et al |
